Study 329

Editorial Note: This post by Leonie Fennel carries on from parts 1 and 2 in this series. There will be one more post. I dreamt I met my son Shane last night - in a jewelry shop, of all places. I was admiring the beautiful costume jewelry, when I overturned the dainty display and went clambering to pick up all the pieces. It seems I don’t escape my klutziness in the land of my … [Read more...] about Club 329: Part 3

Following last week's post, Club 329: Part 1, Ben Goldacre went into orbit claiming his views on medicalization and Study 329 had been misrepresented. He offered a SoundCloud as evidence. The link can be found in the comments after the last post. Seems to me Leonie got the content of the Q & A right. In the course of listening to the BG SoundCloud though something else … [Read more...] about Club 329: Part 2

Editorial Note: This post is by Leonie Fennel. It's one of two involving Leonie. Last week, Dr Ben Goldacre gave a public lecture in the Royal College of Surgeons in Dublin (organised by the 3U Partnership and the very lovely Dr Ruth Davis). Dr Goldacre is a doctor, academic, campaigner and writer; he is also a psychiatrist and self-professed nerd. I was eager to hear what he … [Read more...] about Club 329: Part 1

Editorial Note: This was our final letter in the correspondence that began here and ran through here. There has been no response from Dr Godlee. 28 January 2016 Dr Fiona Godlee Editor, BMJ Re: BMJ handling of conflict of interest Dear Dr Godlee Thank you for your email response of January 11 2016 to our letter of July 8 2015 about Dr Elizabeth Loder's conflict of … [Read more...] about Restoring Study 329: Letter to BMJ Jan 2016

Editorial Note: The posts have gotten slightly out of sequence. This post should have preceded the responses from BMJ. It is the letter to which they were responding. This and other letters are on Study329.org. 8 July 2015 Dr Fiona Godlee Editor BMJ Dear Dr Godlee Re: "Restoring Study 329: A randomised, controlled trial of the efficacy and harms of paroxetine and … [Read more...] about Restoring Study 329: Letter to BMJ

Editorial Note: The letter from the Study 329 team to BMJ re Dr Loder featured in 50 Shades of Gray and in Conflicts of Interest. The actual letter and related correspondence is all on Study329.org.  The emails below and in the next post tell you what happened next. From: Jureidini, Jon (Health) Sent: Wednesday, 8 July 2015 10:32 PM To: fgodlee@bmj.com Subject: 329 and … [Read more...] about Restoring Study 329: Correspondence with BMJ Jul 15 to Jan 16

Editorial Note: This post offers our response to the Keller letter. It was published in BMJ in early February. Again all material is available on Study329.org. The response does not make much of the fact that not all of the Als in Keller et al have lined up to sign their letter. One of the intriguing points in all this is tracking the line taken by GSK and by Keller and … [Read more...] about Study 329: Response to Keller & Colleagues

Editorial Note: Following the publication of Study 329 Restored, Martin Keller and his co-authors gave an initial response in which they said Nobody Pinned Anything on Us and also that they would respond in more detail later. It took four months for this response to appear. Our Response will follow in the next post and after that we will update our background correspondence … [Read more...] about Study 329: Nobody Pinned Anything on Us

Editorial Note: This is the Fourth Crusoe Report. "Death waits for these things like a cement floor waits for a dropping light bulb" Big pharma Study 329 seems to fit the classic picture. It has Big Pharma ghostwriting articles, hiding data, corrupting the scientific process and leaving a trail of death, disability and grieving relatives in its wake. Pharma began in the … [Read more...] about Study 329: Big Risk

Two weeks ago The BMJ ran an editorial by Richard Smith (former editor) and Fiona Godlee (current editor) on the retraction of a 1989 article by R K Chandra under the heading of A Major Failure of Scientific Governance. While making money from the publication of pharmaceutical company trials, and in the face of a complete failure by industry to adhere to basic scientific … [Read more...] about Study 329: BMJ Transparency